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Abstract
Adenovirus (AdV) infections constitute a signiﬁcant cause of morbidity and mortality during haematopoietic stem cell transplantation.
Recent guidelines recommend repeated screening for AdV in whole blood (WB), with quantitative PCR (qPCR) as the reference stan-
dard. Despite pre-emptive antiviral treatment based on qPCR in WB, the mortality rate after disseminated AdV infection remains very
high. The aim of our study was to advance early screening for AdV, using a standardized method, so as to enable the earlier initiation
of antiviral treatment or adoptive immunotherapy. The diagnostic value of AdV DNA quantiﬁcation in stool samples was investigated
retrospectively and compared with antigen detection and cell culture in 21 patients with AdV infection, from 182 patients followed in
the Transplant Unit of Nancy University Hospital Centre, including 18 patients with systemic infection. In 16/18 patients with positive
AdV viraemia, AdV DNA was present in stool samples earlier than in WB (median, 42 days; range, 3–199 days), whereas both antigen
detection and cell culture were still negative for 11/18 patients with systemic AdV infection. The course of AdV viral loads in stool sam-
ples was predictive of adenoviraemia (sensitivity, 89%). Very late and lethal AdV infections were observed in cord blood transplant
recipients, and would have been detected much earlier with the use of qPCR on stool samples. This study conﬁrmed that quantiﬁcation
of AdV in stool samples by qPCR is beneﬁcial for the management of transplant recipients, with or without antigen detection.
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Introduction
Adenovirus (AdV) infections constitute a signiﬁcant cause of
morbidity and mortality after haematopoietic stem cell
transplantation (HSCT) [1]. AdV infections can result from
reactivation or from de novo acquisition, and can be
life-threatening [2]. According to different studies, the risk of
AdV infection ranges from 6% to 68% [3–8], and an increas-
ing incidence has been described, related to the use of
T-cell-depleted transplants [9]. A higher incidence of AdV
infection has been described after HSCT from an unrelated
donor; other signiﬁcant risk factors include younger age,
grade II–IV graft-versus-host disease, anti-thymoglobulin
globulin treatment, and a second allogeneic haematopoietic
stem cell transplant [1]. Treatment options are limited, and
pre-emptive antiviral treatment seems to be ineffective in
preventing death [10].
Recent guidelines recommend repeated screening for
AdV DNA in whole blood (WB) by quantitative PCR
(qPCR) for follow-up of transplant recipients [11]. In the
near future, very early AdV diagnosis will be needed for
the implementation of adoptive immunotherapy [12,13], as
the generation of clinical-grade AdV-speciﬁc T-cells takes
almost 2 weeks [14].
The improvement of AdV detection in stools would be
useful for predicting systemic infection (biologically deﬁned
by positive adenoviraemia) [15]. The diagnostic value of
qPCR for AdV detection in stools as compared with antigen
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detection and cell culture was therefore evaluated in trans-
plant recipients. For a period of 4 years (2005–2008), 21
transplant recipients with AdV detected in stool samples
(deﬁned by positive antigen detection or cell culture), with
or without positive adenoviraemia (AdV DNA detection in
WB), were selected. Retrospectively, AdV DNA in stool
samples was quantiﬁed in the event of positive antigen detec-
tion and cell culture. The course of viral load in stools was
evaluated to deﬁne patients who were at high risk of dissem-
inated AdV infection and who might therefore beneﬁt from
early antiviral treatment or adoptive immunotherapy.
Materials and Methods
Selection of subjects and samples
From 2005 to 2008, 182 consecutive patients underwent
allogeneic HSCT at the Bone Marrow Transplantation Unit
of the Nancy University Hospital Centre: 115 were adults
(>18 years). During these 4 years, 85 bone marrow trans-
plants (BMTs), 64 peripheral blood stem cell transplants
(PBSCTs), 11 cord blood transplants (CBTs) and 22 double
CBTs were performed. One patient received a BMT and a
PBSCT. One patient was transplanted with an ex vivo T-cell-
depleted graft.
Data concerning the detection of AdV by antigen detection
and cell culture, as well as by qPCR in WB, were collected for
30 patients with AdV infection. Molecular screening of AdV
by qPCR in stool samples was available for only 21 patients
(patient characteristics are summarized in Table 1).
AdV detection
All patients were tested for AdV, from day 10 before trans-
plantation (D )10) to day 100 after HSCT (D +100), by cell
culture on MRC5 (RD-Biotech, Besanc¸on, France) from nose,
mouth, throat, vulva, urine and stool samples. In addition, AdV
antigens were screened for in stool samples by ELISA (Premier
Adenoclone; Meridian Bioscience, Nice, France) from 2005 to
2007, and then by immunochromatography (Rapid Strip Rota-
Adeno; Meridian Bioscience) from 2007. All patients were
tested for AdV DNA in WB twice weekly, as described below.
DNA extraction from WB and stool samples
Before March 2006, DNA was manually extracted from
200 lL of WB with the QIAamp DNA Blood Mini kit (Qiagen,
Courtaboeuf, France), according to the manufacturer’s
instructions. From March 2006, DNA was automatically iso-
lated from 200 lL of WB with the Magna Pure LC system
(Roche, Meylan, France), according to the manufacturer’s
instructions. DNA eluted in 100 lL was stored at )80C.
During the study, stool samples from transplant recipi-
ents were systematically stored at )20C. Retrospectively,
DNA was extracted from 200 ± 10 mg of stools with the
QIAamp DNA Stool Mini kit (Qiagen), as recommended by
the manufacturer. DNA was eluted in 200 lL and stored at
)80C.
TABLE 1. Patient demographic and clinical characteristics
Patient
no.
Age
(years) Sex Diagnosis Graft
AdV
type
AdV
viraemia Co-pathogen Treatment Outcome
Clinical diagnosis
of cause of death
Children 503 18 F ES Marrow 1 Yes EBV CDV Dead RSV infection
506 5 F PID Cord blood 1 Yes HHV-6 CDV Dead AdV infection
606 0.7 F ALL Marrow 1 Yes EBV CDV Dead Interstitial pneumonia
564 3 M DS Marrow ND Yes No No Alive –
629 4 M Mu Cord blood 1 Yes HHV-6 CDV Dead AdV infection
636 1 M HS Cord blood 1 Yes No CDV Alive –
624 1 M ALL PBSC 3 No No No Alive –
Adults 548 28 F AML Cord blooda 3 Yes HSV CDV + CTL Dead AdV infection
545 28 F AML Cord blooda 3 Yes HHV-6 CDV + RBV Dead AdV infection
445 30 M ALL Cord blooda 2 Yes No CDV Dead Multi-organ dysfunction
586 25 F ALL PBSC 3 Yes EBV CDV Dead Interstitial pneumonia
575 33 F AML Cord blooda 3 Yes EBV/HHV-6 CDV Dead Multi-organ dysfunction
574 33 M CMML Marrowb 3 Yes EBV CDV Dead Relapse
580 33 M ALL PBSC ND Yes HHV-6 No Alive –
577 24 M HL Marrow ND Yes No No Dead Relapse
622 20 M Leukaemia Marrow 1 Yes CMV CDV Dead Cerebral haemorrhage
651 48 M HL Marrow 2 Yes No CDV + CTL Dead AdV infection
653 37 M AML Marrow 3 Yes CMV CDV Dead Septic shock
640 36 M AML Marrow ND Yes EBV CDV Dead AdV infection
531 37 M ALL Marrow ND No No No Dead Relapse
524 25 M FA Marrow 3 No No No Dead Graft-versus-host disease
AdV, adenovirus; ALL, acute lymphoid leukaemia; AML, acute myeloid leukaemia; CDV, cidofovir; CMML, chronic myelomonocytic leukaemia; CMV, cytomegalovirus; CTL,
adoptive transfer of virus-speciﬁc T-cell immunity; DS, Digeorge syndrome; EBV, Epstein–Barr virus; ES, Ewing’s sarcoma; F, female; FA, Fanconi anaemia; HHV-6, human her-
pesvirus-6; HL, Hodgkin’s lymphoma; HS, Hurler syndrome; HSV, herpes simplex virus; M, male; Mu, mucolipidosis; ND, not determined; PBSC, peripheral blood stem cell;
PID, undeﬁned primitive immune deﬁciency; RBV, ribavirin; RSV, respiratory syncytial virus.
aDouble cord blood.
bSecond graft.
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AdV DNA quantiﬁcation in WB and stool samples was per-
formed by qPCR as previously described by Heim et al. [16],
with an ABI PRISM 7000 (Applied Biosystems, Courtaboeuf,
France). The detection threshold was 30 copies of AdV gen-
ome per 10 lL of DNA extract. A plasmid DNA containing
a partial human AdV 2 hexon sequence, kindly provided by
A. Heim, was serially diluted and used as a template for
qPCR. Results were expressed as copies per millilitre of WB
and copies per gram of stool, with accurate weighing of the
stool sample.
Furthermore, patients were tested weekly by qPCR for
Epstein–Barr virus, cytomegalovirus and human herpesvirus-
6, with the Epstein–Barr virus R-gene kit and the cytomega-
lovirus human herpesvirus-6,7,8 R-gene kit (Arge`ne, Varilhes,
France), on WB samples.
Deﬁnitions
AdV infection was deﬁned by detection of AdV, whatever
the site and whatever the method; systemic AdV infection
was deﬁned by positive adenoviraemia, i.e. repeated detec-
tion (‡2) of AdV DNA in WB by qPCR.
Treatment
The pre-emptive treatment strategy was based on AdV
detection in WB. Antiviral treatment, consisting of cidofovir
infusion (5 mg/kg/week for at least 3 weeks), was established
after two positive AdV qPCR results in WB, and was
stopped after two negative AdV qPCR results in WB. In the
event of cidofovir failure, ribavirin or adoptive transfer of
virus-speciﬁc T-cell immunity, if available, was considered.
Results
AdV infection in the cohort
From 2005 to 2008, among 182 transplant recipients, the
cumulative incidence of AdV infection and viraemia was
16.48% (30/182; 95% CI 11.09–21.87) and 9.89% (18/182;
95% CI 5.55–14.23), respectively. AdV was detected in 14/67
(20.9%) children and 16/115 (13.9%) adults. The transplant
types were distributed as followes: 15 BMTs, ﬁve PBSCTs,
and 10 CBTs, including ﬁve double CBTs.
Among the patients with AdV infection, viraemia devel-
oped in 42.8% (6/14) of the children and in 75% (12/16) of
the adults.
The AdV serotype was determined by haemagglutination
for 16 of 21 patients (B. Lina, Centre Hospitalier Universi-
taire de Lyon, France). Serotype 3 was the most frequently
identiﬁed (Table 1).
Nine patients died from AdV infection, six with a con-
ﬁrmed AdV diagnosis, and three with multi-organ dysfunction
or interstitial pneumonia attributed to AdV, corresponding
to 4.94% (9/182) of the entire cohort and 50% (9/18) of the
patients with invasive infection.
AdV viral load in WB
AdV DNA was systematically quantiﬁed in WB until
D +100. AdV qPCR in WB was performed after that per-
iod, because of clinical symptoms, in patients 575, 564, 577,
and 640. Except for patient 622, who presented AdV DNA
in WB before transplantation, the earliest detection of AdV
viraemia occurred at D +10 (nos. 606 and 629). The med-
ian time for detection of AdV viraemia was D +69 (range,
D )4 to D +518) (Table 2). For the nine patients who died
from AdV infection, the median time to viraemia was
88 days.
AdV detection in stool samples
Weekly stool samples were systematically tested for AdV:
antigen detection remained negative for ﬁve patients, includ-
ing four patients with systemic AdV infection (nos. 574,
580, 577, and 622); all ﬁve patients had positive stool sam-
ples according to qPCR (Table 2). All of the stool samples
were also cultured on MRC5 cells, and, for 17 of the 21
patients included in the study, AdV was isolated from
stools. AdV isolation by cell culture was positive for 15
patients with systemic AdV infection (n = 18), with a
delayed response because of the development of a cyto-
pathic effect.
When viraemia was detected, 12/18 patients presented no
other virological markers of AdV infection (negative antigen
detection in stools, and no AdV isolation by cell culture).
Only three patients (nos. 503, 564, and 653) were positive
for AdV antigen in stools before the detection of AdV DNA
in WB. AdV was isolated from stool samples of six of the 18
patients (Table 3).
In 16/18 patients with systemic infection, AdV DNA was
present in stools earlier than in WB (median, 42 days; range,
3–199 days) (Table 2). In patients with viraemia, the mean
AdV viral load in the previous available stool samples was
5.09 log10 copies/g.
Prognostic value of AdV viral load in stools
One child (no. 636) and two adults (nos. 574 and 626) had
AdV DNA in stools before transplantation, and presented
AdV dissemination in WB as early as D +19, D +27, and
D )4, respectively; before transplantation, AdV antigen
detection in stools by immunochromatography was negative
for these three patients.
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For two adult patients (nos. 580 and 577), a very long
period between the ﬁrst positive qPCR result in stools and
the ﬁrst positive qPCR result in WB was recorded. For
patient 580, increasing viral loads in stools between D +18
and D +175 preceded dissemination of the infection. In
addition, for patient 506, persistent viral load in stools was
predictive of viraemia relapse (Fig. 1a).
The presence of AdV in stools, with a mean virual level of
5.47 log10 copies/g (Fig. 2), and an increased viral load in
stools preceded AdV DNA detection in WB (Fig. 1a,b).
AdV infection in CBT recipients
Thirty-three of the 182 patients received CBTs, including 18
adults and 15 children, and seven developed viraemia. These
seven patients were retrospectively screened for AdV viral
load in stool samples. Three children received simple CBTs,
and two died from AdV disease: patient 629, who developed
systemic infection 10 days after transplantation, and
patient 506, who presented two adenoviraemia peaks at
D +73 and D +143, and a high persistent AdV viral load in
stools (>5 log10/g) between peaks (Fig. 1a).
AdV was detected in four of 18 adults receiving double
CBT (22%), as compared with 12.4% of other transplanted
adults. All four patients (nos. 548, 575, 445, and 545) died
from AdV disease or multi-organ failure caused by AdV.
They developed viraemia later than the other patients in the
cohort: AdV DNA was detected in WB within a median of
143 days post-HSCT vs. 75 days (Fig. 1b).
TABLE 2. Adenovirus diagnosis
Patient
no.
First detection (days after
HSCT) Retrospective PCR in stool samples Time (days)
PCR
in WB
Antigen
in stool
First detection
(days after HSCT)
Maximal value
(log10 copies/g)
PCR in stool/
antigen in stool
PCR in stool/
PCR in WB
503 37 31 13 11.07 18 24
506 73 151 43 11.1 108 30
606 10 17 3 9.9 14 7
564 365 317 215 4.93 102 150
629 10 17 17 11.34 0 )7
636 19 23 )9 3.0 14 28
md = 28 md = 27 md = 15 me = 8.56 md = 16 md = 26
624 ND ND 10 6.77 NA NA
548 65 67 10 9.37 57 55
545 197 205 12 10.55 193 185
445 88 99 32 12.26 67 56
586 58 67 3 4.54 70 61
575 214 245 245 9.96 0 )31
574 27 ND )8 11.48 NA 35
580 175 ND 18 8.9 NA 157
577 518 ND 319 5.17 NA 199
622 )4 ND )7 12.64 NA 3
651 90 108 14 9.66 94 76
653 59 55 10 10.49 45 49
640 241 245 217 9.87 28 24
md = 133 md = 108 md = 16 me = 9.46 md = 45 md = 63
531 ND 17 7 10.54 10 NA
524 ND 40 34 4.3 6 NA
Total md = 69 md = 67 md = 13.5 me = 9.05 md = 36.5 md = 42
HSCT, haematopoietic stem cell transplantation; md, median; me, mean; NA, not applicable; ND, not detectable; WB, whole blood. Patients 503 to 636, children with
viraemia; patient 624, children without viraemia; patients 548 to 640, adults with viraemia; patients 531 and 524, adults without viraemia.
TABLE 3. Detection of adenovirus (AdV) in stool samples, as compared with antigen detection, cell culture, or quantitative
PCR (qPCR), at the onset of systemic AdV infection (ﬁrst detection of AdV DNA in whole blood by qPCR) (N = 18)
AdV antigen in
stoola (+)
AdV antigen
in stoola ())
Stool cell
culture (AdV+)
Stool cell
culture (AdV))
AdV DNA in stoolb (+), n 3 13 5 11
AdV DNA in stoolb ()), n 0 2 1 1
Prognostic value for adenoviraemia qPCR in stool AdV antigen in stool Cell culture in stool
Sensitivity (%) 88.89 18.75 27.78
aImmunochromatography or ELISA.
bQuantitative PCR [16].
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Treatment
Of the 18 patients with AdV viraemia, 12 were treated with
cidofovir alone, one (no. 545) received cidofovir and ribavi-
rin, two (nos. 548 and 651) were treated with adoptive
transfer of virus-speciﬁc T-cell immunity after cidofovir fail-
ure, and three (nos. 580, 577, and 564) were not treated.
Despite antiviral treatments, Kaplan–Meier analysis revealed
a cumulative survival rate at 24 months of 7% for treated
patients with systemic AdV infection.
Discussion
AdV infection is a rare but serious infectious complication
after allogeneic HSCT [1]. The general characteristics of our
transplant recipient cohort are similar to those described in
other transplant centres: the percentage of systemic AdV
infection reached 9.89%, as compared with 4.8–15% found in
previous studies [8,10,17,18]. The incidence of AdV infection
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FIG. 1. Course of adenovirus (AdV) DNA
load (h) in whole blood (log10 copies/mL) and
(s) in stool samples (log10 copies/g) in
haematopoietic stem cell transplant recipients.
›: treatment start date. HSCT, haemato-
poietic stem cell transplantation.
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FIG. 2. Adenovirus (AdV) viral loads in stool
samples in haematopoietic stem cell transplant
recipients with systemic AdV infection before
positive adenoviraemia (s), or during systemic
infection (d) (positive AdV DNA detection in
whole blood) and in stool samples of
haematopoietic stem cell transplant recipients
with localized AdV infection ()). The
discontinuous line represents the mean viral
load in stool samples before dissemination of
systemic AdV infection in the whole blood
compartment.
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in children (21%, 14/67) was also comparable with that of
other studies [17,19], and the median time to detection of
AdV in WB (D +69) was close to that described in the liter-
ature [17]. All of the patients who presented positive detec-
tion of AdV DNA in WB had at least one risk factor: young
age, second transplantation, acute graft-versus-host disease
(‡II), anti-thymoglobulin globulin treatment, and/or CBT in
adults.
A preliminary study performed in our hospital [20] has
demonstrated the beneﬁt of early antiviral treatment in
terms of better outcome for infection and a decrease in
renal complications.
Since 2005, 21 patients have been screened retrospectively
for AdV viral load in stool samples by qPCR. The use of a criti-
cal value for viral load in stools requires a reliable unit (i.e.
grams), so accurate AdV DNA quantiﬁcation was performed
in stool samples with weighed samples. The homogeneity of
viral load values in different samples of the same stool was also
investigated and validated (data not show).
Retrospective qPCR in stools showed the relatively low
predictive value of cell culture and AdV antigen in stool sam-
ples for initiation of antiviral treatment. In our cohort of
AdV-infected transplant recipients, AdV isolation by cell cul-
ture was negative for 67% of the stool samples at the time
of AdV viraemia. Mostly, antigen detection remained negative
in stool samples when AdV DNA was detected in WB, even
when the AdV serotype was supposed to be detected by the
test, according to the kit assay manufacturer. qPCR on stool
samples gave positive results, on average, 58 days before the
positive detection of AdV antigen, owing to the extremely high
sensitivity of the qPCR assay. In some cases, the lack of antigen
detection may be explained by the fact that the assay does not
detect all of the AdV serotypes (patients 580 and 577, with
undeﬁned serotypes, were negative for antigen detection in
stool samples, and positive with qPCR). The time advantage
found for viral load in stools was beneﬁcial in comparison with
the late diagnosis made by antigen detection. A recently pub-
lished prospective study conﬁrmed the excellent sensitivity
and speciﬁcity of qPCR on stools in predicting viraemia [15].
Similarly, a recent study of 62 children undergoing HSCT
found that detection of AdV by qPCR in nasopharyngeal aspi-
rate was a predictor of adenoviraemia [21]. qPCR on both
stool and nasopharyngeal aspirate samples could be combined
with qPCR on WB to allow pre-emptive treatment before the
development of a serious systemic infection.
Our study also underlined the extremely high incidence of
systemic infection and AdV-associated mortality in CBT
recipients, which is explained by the fact that the cord blood
graft does not carry the mature lymphoid cells required for
anti-infectious immunity [17]. In our study, all CBT recipients
(4/4 adults) died from severe AdV infection. For three of
them, qPCR on stool samples would probably have pre-
vented AdV dissemination if treatment had been initiated
earlier, as the viral load in stools was positive as early as
185 days (no. 545) before that in WB. The use of qPCR on
stool samples and WB would be even more beneﬁcial to
those patients, and longer (>100 days) monitoring for AdV
infection would be warranted.
Current strategies for treating AdV disease are based on
the pre-emptive treatment of patients presenting with
adenoviraemia [10]. Treatment options for adenoviral dis-
ease are limited. Cidofovir appears to be safe and effective
for the treatment of AdV infection [19], whereas ribavirin
displays type-speciﬁc antiviral activity [22]. Although antiviral
treatment of AdV infection may beneﬁt severely immuno-
compromised patients [19,23], a high mortality rate contin-
ues to be observed, particularly in patients who do not
respond to cidofovir [17,18]. The viral load threshold in
WB that is needed to justify pre-emptive treatment has
been described as 4 · 103 copies/mL in WB [24], but this
has not yet been validated. The presence of AdV DNA in
stool samples could be a predictive marker of AdV infec-
tion dissemination and therefore used for therapeutic deci-
sion-making before AdV infection dissemination. The critical
threshold of 106 copies/g, proposed by Lion et al. [15] as a
predictor of imminent viraemia, is consistent with the
course of AdV viral loads in stools and WB observed in
our study. With the use of stool qPCR and this threshold,
11 patients would have been treated earlier than with the
use of antigen detection. On the basis of these data, stool
qPCR could be proposed for the initiation of early antiviral
therapy to halt or delay viraemia.
In conclusion, quantiﬁcation of AdV in stool samples by
qPCR proved to be a useful tool for monitoring transplant
recipients. qPCR in stool samples could be performed in
association with the identiﬁcation of speciﬁc circulating
T-cells in high-risk patients [25,26]. The threshold of
106 log10 copies of AdV DNA per gram of stools must be
validated in further prospective studies. As AdV infection
control seems to require antigen-speciﬁc T-cells [3], further
use of clinical-grade human anti-AdV cytotoxic cells is an
attractive option [13], and could be based on AdV viral load
in stool samples.
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